United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

United Therapeutics Corporation (NASDAQ ... Our latest SEC filings, including Forms 10-Ks and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations ...

United Therapeutics (UTHR) reported $735.9 million ... With the consensus EPS estimate being $6.10, the EPS surprise was +1.48%. While investors scrutinize revenue and earnings changes year ...

United Therapeutics (UTHR) came out with quarterly earnings of $6.19 per share, beating the Zacks Consensus Estimate of $6.10 per share. This compares to earnings of $4.36 per share a year ago.

Finally, HC Wainwright restated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. 10 Stocks to Sell NOW! 3 Stocks to DOUBLE ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the ...